Form 4: Edwards Lifesciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On October 15, 2024, Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences Corp, exercised employee stock options to acquire 5,000 shares of common stock at a price of $45.2767 per share.
• Simultaneously, Bobo sold 5,000 shares of common stock at a weighted average price of $69.5067 per share, with individual sales prices ranging from $69.34 to $69.69.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
• Following these transactions, Bobo directly owns 46,935.7184 shares of common stock.
• Bobo also indirectly owns 38,616.6145 shares through a 401(k) and 135,152 shares through a trust.
• He continues to hold options for 40,500 shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Positives

• The transactions were pre-planned under a 10b5-1 trading plan, indicating no insider information was used.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows insiders to trade company stock without being accused of acting on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to avoid accusations of insider trading.
• Comparable companies such as Medtronic, Abbott Laboratories, and Boston Scientific also see regular Form 4 filings from their executives.

Stakeholder Impact

• The transactions have a minimal direct impact on shareholders, as they represent a small percentage of the total outstanding shares.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates